Home About Products & Services News Research Investors Contact

To learn more about the NeuroStar TMS Therapy System, visit our product website.


Neuronetics has developed the NeuroStar TMS Therapy® system, the first and only non-systemic and non-invasive TMS system for the treatment of depression. It was recently cleared by the U.S. Food and Drug Administration (FDA) for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication.* This non-invasive treatment for depression uses highly focused, pulsed magnetic field to stimulate function in targeted brain regions.

NeuroStar TMS Therapy is a 37-minute outpatient procedure that is available by prescription only and is performed under the supervision of a psychiatrist. It does not require anesthesia or sedation, and patients remain awake and alert during the procedure. Treatment is administered daily for four to six weeks (20-30 treatments).

* NeuroStar TMS Therapy® is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode. Click here for full prescribing and safety information

Find a NeuroStar TMS Therapy Provider Near You

If you or a loved one is suffering from major depression, you can find a NeuroStar TMS Therapy provider in your area.

Provide NeuroStar TMS Therapy in Your Practice

Provide your patients the new way back with NeuroStar TMS Therapy®. Contact us to find out how you can begin providing therapy.

This link provides you with access to recent published information and news about NeuroStar TMS Therapy and new options for the treatment of depression. Neuronetics does not provide any assurances of the accuracy of this information and may not agree with the opinions of the authors.

NeuroStar TMS Therapy is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode. To return to the Neuronetics website for full safety and prescribing information click here.

Click here to continue.